Oxiracetam has not demonstrated a robust, lasting cognitive benefit for healthy adults seeking to improve their everyday memory or attention. Yet genuine human studies exist, including recent clinical trials. Ignoring them would be just as misleading as presenting them as validation of biohacking.
The decisive question is specific: which form, in whom, and with what measured outcome? A patient after a traumatic brain injury, a volunteer taking a drug that induces amnesia and a healthy student do not answer the same question.
This evidence dossier, checked on 16 October 2026, offers no purchasing advice, dosing or self-experimentation protocol. The guide to racetams, their evidence and risks · FR introduces the family. Here, the analysis concerns oxiracetam and the forms studied.
Identity, isomers and the racetam family
Chemical kinship does not guarantee a shared effect
Oxiracetam belongs to the pyrrolidone derivatives grouped among the racetams. It is not a peptide. Its relationship to piracetam does not give it the same indications or regulatory status.
Experimental research explores neurotransmission, brain metabolism and the consequences of vascular or traumatic injuries, among other areas. These avenues describe possible mechanisms. They cannot tell us how many words a healthy person will remember after taking it.
The label “nootropic” is a research or marketing category, not a level of clinical evidence.
Racemic, R, S and L: read the exact formulation
A chiral molecule can have two mirror-image forms, called enantiomers. For oxiracetam, these are the R and S forms. The racemic mixture combines them in equal proportions. An S-oxiracetam preparation is therefore not the same thing as this mixture.
The clinical protocol published in 2024 specifies that S-oxiracetam is called “L-oxiracetam” in this programme. This documented correspondence must not become a general rule conflating all R/S and L/D chemical notation.
The useful distinction is as follows:
| Designation | Identity studied | Shortcut to avoid |
|---|---|---|
| Racemic oxiracetam | Mixture of the R and S enantiomers | Directly attributing results from an isolated S form to it |
| S-oxiracetam | One specific enantiomer | Assuming that activity in animals guarantees a cognitive effect in humans |
| L-oxiracetam in LOCATE | Name for S-oxiracetam in this clinical programme | Declaring all formulations interchangeable |
| Reagent or analytical standard | Product labelled for laboratory use | Treating it as a medicine intended for consumption |
In a 2017 study in rats with cerebral hypoperfusion, the S form improves some spatial learning and memory outcomes, unlike the R form in this model. This supports distinguishing between the enantiomers. It does not establish universal superiority in healthy humans.
Crucially, S-oxiracetam is no longer solely a preclinical research topic: phase I trials and a phase 3 trial have since been published. The verdict must incorporate these results, along with their populations and limitations.
Study table by population
This matrix selects studies that change how the promises should be interpreted. Recent trials following brain injury were reviewed in full text. For some older publications and the oral phase I trial, the analysis relies on indexed abstracts, without a full audit of each protocol.
| Formulation and study | Population | Outcomes actually measured | Result and limitation |
|---|---|---|---|
| Oxiracetam, 1987 publication | Healthy volunteers and patients in three separate studies | EEG, psychometric tests, tolerability and clinical assessments | Favourable signals reported, but the abstract does not allow a reliable estimate of everyday benefit in healthy people |
| Oxiracetam, 1995 trial | 12 healthy volunteers given scopolamine | Verbal recall, semantic memory and attention during induced amnesia | Signal on some performance measures, in a pharmacological model of impairment |
| Oral S-oxiracetam, 2023 phase I trial | Healthy adults | Tolerability, concentrations, elimination and accumulation | Safety and pharmacokinetic information, without evidence of cognitive improvement |
| S, R and racemic mixture, 2017 study | Rats with cerebral hypoperfusion | Spatial learning, memory and tissue markers | Signal favouring the S form in this animal model |
| L-oxiracetam, oxiracetam and placebo, LOCATE, 2025 | 590 patients after mild to moderate traumatic brain injury | LOTCA cognitive score at 90 days, other assessments and adverse events | Primary outcome favourable to L-oxiracetam, without validation in healthy adults |
| Oxiracetam versus placebo, 2026 publication | 500 patients randomised after stroke, 457 with primary outcome data | MMSE and CDR-SB after 36 weeks | No demonstrated benefit on either primary outcome |
The sources are the publications from 1987, 1995, phase I in 2023, LOCATE in 2025 and the post-stroke trial. Different bibliographic listings of the same trial must not be counted as independent replications.
Memory and attention: the outcomes actually measured
A healthy volunteer can be studied in an artificial setting
The scopolamine trial includes twelve initially healthy people. But the drug impairs performance, and the researchers then assess whether oxiracetam mitigates some of its effects.
The findings concern delayed recall of word lists, among other outcomes. Reducing an induced deficit does not mean boosting everyday memory beyond its normal functioning. This model is equivalent to neither a working day nor learning tracked over several months.
Older studies reporting psychometric effects in volunteers mean we cannot claim there has been no research at all. They are no substitute for a body of modern, adequately powered trials replicated under conditions that match the promise.
A genuine clinical finding after traumatic brain injury
In LOCATE, L-oxiracetam administered intravenously in hospital improves the LOTCA score compared with placebo. The adjusted difference at 90 days is 8.97 points, with a 95% confidence interval of 5.69 to 12.26.
The finding deserves to be reported. However, 146 of the 590 participants had not reached the 90-day assessment, making analyses of missing data important. Declared support includes the supply of study drugs and a contribution from Nanjing Yoko Biomedical towards editorial and consulting services.
This clinical finding cannot predict a gain in someone without a brain injury. Nor does the hospital treatment studied validate an oral powder with a similar name.
A post-stroke trial that does not confirm a general benefit
The multicentre post-stroke trial reports a change in MMSE of +0.13 points with oxiracetam versus +0.27 with placebo, with no statistically significant difference. The second primary outcome, CDR-SB, also shows no significant difference.
Overall, the group studied showed little decline. This limits the ability to demonstrate a preventive effect, without turning a negative result into a positive one. Declared funding came from Korean Drug Company, with the authors stating that the funder had no role in the design, analysis or decision to publish.
Exploratory imaging or subgroup findings must not take the place of these primary outcomes. This trial and LOCATE are not directly contradictory: they differ in the injury, formulation, participants and clinical question.
A score does not translate into a “percentage more brainpower”
LOTCA is a cognitive assessment used in rehabilitation. The MMSE is a global tool that does not, on its own, isolate sustained attention or everyday learning. Word recall is yet another outcome.
To assess a promise about memory or concentration, look for answers to these questions:
- Do the participants resemble the target population?
- Was the outcome prespecified as a primary outcome?
- Is the improvement seen against placebo, rather than just compared with baseline?
- Is its magnitude enough to change everyday functioning?
- Does the benefit persist, and has it been replicated?
A battery of many tests also increases the chances of finding an isolated positive result. Conclusions must account for the outcome hierarchy and multiple comparisons.
Tolerability and unknowns
A phase I trial mainly informs us about exposure and immediate safety
The oral phase I trial of S-oxiracetam reports mild to moderate adverse events and examines absorption and elimination. This is useful for clinical development. It proves neither the absence of rare effects nor the safety of prolonged use to improve performance.
Another pharmacokinetic study in 52 volunteers examines intravenous S-oxiracetam. It does not demonstrate a benefit for exam revision or productivity either. The route of administration is part of the finding: you cannot erase it to make a study apply to a different product.
Kidney function matters
A study in twenty patients with varying renal function shows that oxiracetam elimination depends on renal function. Kidney disease may therefore alter exposure. The fact that a substance is eliminated largely unchanged does not guarantee its safety.
This finding calls for medical supervision, not DIY dose calculations. The data on interactions, prolonged use in healthy people, pregnancy, breastfeeding and minors do not support a recommendation for safe use here.
Piracetam’s properties should not serve as a substitute information leaflet for oxiracetam. Even within the same family, adverse effects and interactions require assessment molecule by molecule.
The commercial product adds uncertainty
A laboratory product, an analytical standard and a medicine do not serve the same purpose. A stated purity alone does not document the full composition, impurities, stability, microbiological quality or equivalence to a clinical formulation.
The DGCCRF warns of the risks of health products purchased outside authorised channels. I do not have a representative contamination rate for products labelled oxiracetam. Inventing one would be misleading, as would guaranteeing their quality based on a single certificate.
If memory difficulties appear or worsen, seek medical advice rather than masking the problem. An assessment can look for causes related to sleep, mood, medication or disease. After exposure, an unusual symptom warrants medical advice: provide the product name and details of any other substances taken. Sudden confusion, weakness on one side, difficulty speaking or feeling severely unwell require urgent help: call 15 or 112 in France.
French regulatory status and the distinction from a reagent
Dated check of the relevant registers
As of 16 October 2026, searches for oxiracétam, oxiracetam and the identifiers ISF-2522 and CT-848 found no matches in the French medicinal product and composition files examined. A text search of the EMA medicines table also found no matches.
The BDPM medicinal product and composition files consulted are dated 29 September 2026. The EMA table is an export from 16 October 2026. The EMA catalogue does not cover all national authorisations: it must be cross-checked against French sources.
No corresponding marketing authorisation was identified within this scope. This finding is not an exhaustive analysis of all exceptional access schemes or the laws governing possession and importation. It does not mean oxiracetam can automatically be considered an authorised food supplement.
A reagent catalogue indicates commercial availability for a stated use. It is neither a medical information leaflet nor authorisation for administration to humans.
What does an Orphanet entry mean?
An entry in a rare disease database may refer to a substance in development, an orphan designation or a medicine authorised in a specific territory and indication. You therefore need to check the type of status, its territory and its regulatory source, rather than just the molecule’s name.
To clarify the situation for oxiracetam, the primary FDA record lists an orphan designation dated 15 May 2025 for Duchenne muscular dystrophy. It specifies that there is no FDA approval for this orphan indication.
The FDA explains that an orphan designation is separate from an approval process. It supports the development of a potential treatment without proving that its efficacy has been established for marketing approval.
This listing therefore demonstrates neither a memory benefit in healthy adults nor a French marketing authorisation. A documentary register does not prove efficacy in another indication.
